Composition for enzyme inhibition

Details Composition for enzyme inhibition Composition for enzyme inhibition

2005-12-07

2010-06-15

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S017400, C514S018700, C514S058000, C536S046000, C536S103000, C536S112000

Reexamination Certificate

active

07737112

ABSTRACT:
Compositions comprising one or more practically insoluble proteasome inhibitors and a cyclodextrin, particularly a substituted cyclodextrin, substantially increase the solubility of these proteasome inhibitors and facilitate their administration. Such compositions optionally comprise a buffer. Methods of treatment using such compositions are also disclosed.

REFERENCES:
patent: 5134127 (1992-07-01), Stella et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5376645 (1994-12-01), Stella et al.
patent: 5441944 (1995-08-01), Weisz et al.
patent: 5874418 (1999-02-01), Stella et al.
patent: 6046177 (2000-04-01), Stella et al.
patent: 6133248 (2000-10-01), Stella
patent: 6831099 (2004-12-01), Crews et al.
patent: 2003/0236223 (2003-12-01), Wagner et al.
patent: 2005/0101781 (2005-05-01), Agoulnik et al.
patent: WO-01/28579 (2001-04-01), None
patent: WO-2005/105827 (2005-11-01), None
patent: WO-2005/111008 (2005-11-01), None
patent: WO-2006/017842 (2006-02-01), None
Meng (Cancer Research 59, 2798, 1999).
Elofsson et al., “Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′, β′-epoxyketones”,Chemistry&Biology, 6:811-822 (1999).
Loftsson et al., “Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabalization,”Journal of Pharmaceutical Sciences, American Pharmaceutical Association, 85(10):1017-1025 (1996).
Myung et al., “Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors,”Molecular Cell, 7(2):411-420 (2001).
Sin et al., “Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology”,Bioorganic&Medicinal Chemistry Letters, 9:2283-2288 (1999).
Thompson D.O., “Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals,”Critical Reviews in Therapeutic Drug Carrier Systems, 14(1):1-104 (1997).
Strickley, Robert G., “Solubilizing Excipients in Oral and Injectable Formulations,” Pharmaceutical Research, 21(2):201-230 (2004).
Tong, Wei-Qin (Tony), “Applications of Complexation in the Formulation of Insoluble Compounds,” R. Liu, Ed., pp. 111-139 (2000).

Affiliated with

Also associated with

Rating

Composition for enzyme inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition for enzyme inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for enzyme inhibition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4173990